Adjuvant Novel Nanocarrier-Based Targeted Therapy for Lung Cancer

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Lung cancer has a low survival rate due to late diagnosis, poor prognosis, and tumor heterogeneity, limiting treatment effectiveness.
• The tumor microenvironment (TME) releases factors that impede conventional therapies.
• Personalized adjuvant therapies, including targeted drug delivery, are crucial for improving treatment outcomes.

Purpose of the Study:

• To explore the role of nanocarriers in improving lung cancer treatment effectiveness by targeting the TME.
• To investigate strategies for enhancing nanocarrier penetration and function within the TME.
• To evaluate the potential of biofunctionalized nanocarriers for personalized non-small cell lung cancer (NSCLC) therapy.

Main Methods:

• Utilizing biofunctionalized nanocarriers to enhance interaction with biological systems, cellular uptake, and immune escape.
• Employing inorganic metal compounds for reactive oxygen species (ROS) scavenging via photothermal effects.
• Conjugating or modifying nanocarriers with agents to modulate the TME, including extracellular matrix (ECM), cancer-associated fibroblasts (CAFs), TAMs, Tregs, and MDSCs.

Main Results:

• Biofunctionalized nanocarriers facilitate penetration into the TME by stimulating vascular changes and immune system escape.
• Inorganic metal compounds within nanocarriers can scavenge ROS through photothermal effects.
• Modified nanocarriers, when co-administered with other agents, can regulate key components of the TME, such as CAFs and suppress T-cells.

Conclusions:

• Nanocarriers, particularly those with biofunctionalized inorganic metal compounds and complex-loaded drugs, show promise for targeted NSCLC therapy.
• Strategies involving nanocarrier modification and conjugation enhance active targeting and TME penetration.
• Personalized nanocarrier-based approaches hold potential for overcoming treatment resistance in lung cancer.